# AVXL (Anavex Life Sciences Corp.) - SEC EDGAR Financial Statements

> Anavex Life Sciences Corp. reported $120.1M in total assets and a net loss of $13.02M through September 30, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/AVXL
- Markdown: https://convexityos.com/fundamentals/AVXL.md
- SEC CIK: 0001314052
- Reporting currency: USD
- Latest filing period: June 30, 2026
- Last synced: Nov 20, 2026, 05:49 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001314052&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Sep 30, 2025 |
| Operating Income | FY 2025 | -$17.37M | Operating profit |
| Net Income | FY 2025 | -$13.02M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$0.00 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Jun 30, 2026 | $118.3M | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $37.59M | $41.84M | $43.72M | $37.92M | $32.98M | $25.23M | $22.26M | $13.34M | $10.67M | $7.25M |
| Selling, General & Admin | $13.82M | $11.04M | $12.05M | -- | -- | -- | -- | -- | -- | -- |
| Total Operating Expenses | $51.41M | $52.88M | $55.76M | $50.99M | $42.00M | -$31.09M | $29.11M | $19.33M | $15.68M | $15.59M |
| **Operating Income** | -$51.41M | -$52.88M | -$55.76M | -$50.99M | -$42.00M | -$31.09M | -$29.11M | -$19.33M | -$15.68M | -$15.59M |
| **EBITDA** | -- | -- | -- | -- | -- | -- | -- | -- | -- | -$15.59M |
| Income Before Tax | -$46.38M | -$43.00M | -$47.50M | -$47.62M | -$37.64M | -$26.26M | -$26.21M | -$17.18M | -$13.40M | -$14.71M |
| **Net Income** | -$46.38M | -$43.00M | -$47.51M | -$47.98M | -$37.91M | -$26.28M | -$26.29M | -$17.25M | -$13.46M | -$14.74M |
| Basic EPS | -$0.54 | -$0.52 | -$0.60 | -$0.62 | -$0.54 | -$0.45 | -$0.54 | -$0.39 | -$0.33 | -$0.42 |
| **Diluted EPS** | -$0.54 | -$0.52 | -$0.60 | -$0.62 | -$0.54 | -$0.45 | -$0.54 | -$0.39 | -$0.33 | -$0.42 |
| Basic Shares Outstanding | 85.3M | 83.5M | 79.8M | 76.9M | 69.8M | 58.2M | 48.9M | 44.7M | 40.8M | 35.2M |
| Diluted Shares Outstanding | 85.3M | 83.5M | 79.8M | 76.9M | 69.8M | 58.2M | 48.9M | 44.7M | 40.8M | 35.2M |

### Income Statement (Quarterly)

| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | -- | $4.19M | $4.66M | $7.29M | $9.96M | $9.89M | $10.45M | $11.61M |
| Selling, General & Admin | $2.03M | $2.29M | $2.13M | $3.55M | $4.50M | $2.62M | $3.15M | -- |
| Total Operating Expenses | -$6.74M | $6.48M | $6.78M | $10.84M | $14.46M | $12.51M | $13.59M | $14.27M |
| **Operating Income** | $6.74M | -$6.48M | -$6.78M | -$10.84M | -$14.46M | -$12.51M | -$13.59M | -$14.27M |
| Income Before Tax | -- | -- | -- | -- | -- | -- | -- | -$11.74M |
| Income Tax Expense | $0 | $0 | $18K | -- | -- | -- | -- | -- |
| **Net Income** | $7.82M | -$5.34M | -$5.68M | -$9.83M | -$13.24M | -$11.20M | -$12.11M | -$11.62M |
| Basic EPS | $0.08 | -$0.06 | -$0.06 | -- | -$0.16 | -$0.13 | -$0.14 | -- |
| **Diluted EPS** | $0.08 | -$0.06 | -$0.06 | -- | -$0.16 | -$0.13 | -$0.14 | -- |
| Basic Shares Outstanding | 92.70B | 92.7M | 89.0M | -- | 85.38B | 85.1M | 84.8M | -- |
| Diluted Shares Outstanding | 92.90B | 92.7M | 89.0M | -- | 85.38B | 85.1M | 84.8M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $102.6M | $132.2M | $151.0M | $149.2M | $152.1M | $29.25M | $22.19M | $22.93M | $27.44M | $9.19M |
| **Cash & Short-Term Investments** | $102.6M | $132.2M | $151.0M | $149.2M | $152.1M | $29.25M | $22.19M | $22.93M | $27.44M | $9.19M |
| **Total Current Assets** | -- | -- | -- | -- | -- | -- | $25.33M | $26.05M | $27.79M | $9.45M |
| **Total Non-Current Assets** | -- | -- | -- | -- | -- | -- | $0 | $154K | $52K | $52K |
| **Total Assets** | $103.8M | $135.6M | $154.4M | $152.7M | $161.6M | $34.54M | $25.33M | $26.21M | $27.84M | $9.50M |
| Accounts Payable | $4.25M | $9.63M | $4.32M | $3.83M | $4.74M | $3.99M | $3.52M | $2.96M | -- | -- |
| **Total Current Liabilities** | -- | -- | -- | -- | $10.80M | $7.31M | $5.04M | $3.88M | $3.58M | $3.19M |
| **Total Non-Current Liabilities** | -- | -- | -- | -- | $0 | $0 | $0 | $0 | $0 | $0 |
| **Total Liabilities** | $8.95M | $15.30M | $12.53M | $10.21M | $10.80M | $7.31M | $5.04M | $3.88M | $3.58M | $3.19M |
| Common Stock | $87K | $85K | $82K | $78K | $76K | $62K | $53K | $46K | $43K | $36K |
| Retained Earnings | -$382.4M | -$336.1M | -$293.1M | -$245.6M | -$197.6M | -$159.7M | -$133.4M | -$107.1M | -$91.48M | -$78.02M |
| **Total Stockholders' Equity** | $94.87M | $120.3M | $141.9M | $142.5M | $150.8M | $27.24M | $20.29M | $22.32M | $25.88M | $6.31M |
| Total Equity | $94.87M | $120.3M | $141.9M | $142.5M | $150.8M | $27.24M | $20.29M | $22.32M | $25.88M | $6.31M |

### Balance Sheet (Quarterly)

| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $118.3M | $127.4M | $131.7M | $102.6M | $101.2M | $115.8M | $120.8M | $132.2M |
| **Cash & Short-Term Investments** | $118.3M | $127.4M | $131.7M | $102.6M | $101.2M | $115.8M | $120.8M | $132.2M |
| **Total Assets** | $120.1M | $128.8M | $133.0M | $103.8M | $102.4M | $117.1M | $124.0M | $135.6M |
| Accounts Payable | $3.66M | $2.52M | $2.64M | $4.25M | $6.74M | $7.00M | $4.57M | $9.63M |
| **Total Liabilities** | $7.69M | $7.06M | $6.37M | $8.95M | $11.47M | $17.38M | $13.13M | $15.30M |
| Common Stock | $93K | $93K | $93K | $87K | $85K | $85K | $85K | $85K |
| Retained Earnings | -$385.6M | -$393.5M | -$388.1M | -$382.4M | -$372.6M | -$359.4M | -$348.2M | -$336.1M |
| **Total Stockholders' Equity** | $112.4M | $121.7M | $126.6M | $94.87M | $90.96M | $99.76M | $110.9M | $120.3M |
| Total Equity | $112.4M | $121.7M | $126.6M | $94.87M | $90.96M | $99.76M | $110.9M | $120.3M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$46.38M | -$43.00M | -$47.51M | -$47.98M | -$37.91M | -$26.28M | -$26.29M | -$17.25M | -$13.46M | -$14.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- | -- | -- | -- | -- | $1.3K |
| Stock-Based Compensation | $11.55M | $9.44M | $16.37M | $18.38M | $8.23M | $4.88M | $6.43M | $5.52M | $4.14M | $5.06M |
| Change in Receivables | -- | -- | -- | -- | -- | -- | -- | -$30K | $54K | -$2.5K |
| Change in Payables | -$5.38M | $5.30M | $497K | -$914K | $751K | $466K | $684K | $38K | -- | -- |
| **Operating Cash Flow** | -$39.04M | -$30.81M | -$27.79M | -$24.24M | -$30.38M | -$21.29M | -$18.53M | -$12.58M | -$9.02M | -$9.24M |
| Common Stock Issued | -- | $11.28M | $27.88M | $20.98M | $153.2M | $28.75M | $17.83M | $8.17M | $27.27M | $3.17M |
| **Financing Cash Flow** | $9.43M | $11.97M | $29.65M | $21.29M | $153.2M | $28.35M | $17.78M | $8.07M | $27.27M | $3.13M |
| **Net Change in Cash** | -$29.61M | -$18.84M | $1.87M | -$2.95M | $122.9M | $7.06M | -$745K | -- | -- | -- |

### Cash Flow Statement (Quarterly)

| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | $7.82M | -$5.34M | -$5.68M | -$9.83M | -$13.24M | -$11.20M | -$12.11M | -$11.62M |
| Stock-Based Compensation | -$17.08M | $314K | $1.11M | $3.72M | $4.32M | $1.45M | $2.06M | $2.01M |
| Change in Payables | $1.14M | -$119K | -$1.61M | -$2.49M | $2.01M | $167K | -$5.06M | $6.07M |
| **Operating Cash Flow** | -$9.10M | -$4.44M | -$7.15M | -$8.60M | -$12.46M | -$5.86M | -$12.12M | -$6.66M |
| **Financing Cash Flow** | $0 | $113K | $36.32M | $10.02M | -$2.14M | $852K | $708K | $89K |
| **Net Change in Cash** | -$9.10M | -$4.33M | $29.17M | $1.41M | -$14.61M | -$5.00M | -$11.41M | -$6.57M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -48.9% | -35.8% | -33.5% | -33.7% | -25.1% | -96.5% | -129.6% | -77.3% | -52.0% | -233.6% |
| Return on Assets (ROA) | -44.7% | -31.7% | -30.8% | -31.4% | -23.5% | -76.1% | -103.8% | -65.8% | -48.4% | -155.1% |
| Current Ratio | -- | -- | -- | -- | -- | -- | 5.03x | 6.71x | 7.75x | 2.96x |
| Quick Ratio | -- | -- | -- | -- | 14.09x | 4.00x | 4.40x | 5.90x | 7.66x | 2.88x |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -11.6% | -28.0% | -31.5% | -48.9% | -53.0% | -47.3% | -41.9% | -35.8% |
| Return on Assets (ROA) | -10.8% | -26.5% | -30.0% | -44.7% | -47.0% | -40.2% | -37.5% | -31.7% |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
